IBIO Overview

Exicure, Inc. Surge: Exicure, Inc. saw a significant after-hours increase of 72.61% to $9.20 following positive Phase 2 trial results for its therapy in multiple myeloma patients, with 90% of participants achieving the primary endpoint.

Artiva Biotherapeutics and iBio Performance: Artiva Biotherapeutics rose 10.39% after hours despite a regular session decline, while iBio advanced 8.38% after hours, continuing its earlier gains without any new announcements.

Cartesian Therapeutics and Metagenomi Gains: Cartesian Therapeutics increased 6.55% after hours, while Metagenomi gained 7.18% after hours, with the latter planning to present preclinical data at an upcoming conference.

Wave Life Sciences and Assembly Biosciences Updates: Wave Life Sciences shares rose 4.97% after hours following a public offering announcement, and Assembly Biosciences gained 5.96% after reporting positive interim results from Phase 1b studies of its investigational HSV inhibitors.

IBIO-610 Overview: iBio, Inc. has announced promising preclinical data for IBIO-610, a potential first-in-class Activin E antibody, showing significant fat-selective weight loss and prevention of weight regain in a diet-induced obesity mouse model.

Extended Half-Life Findings: New data from non-human primate studies indicates an extended half-life of 33.2 days, with a predicted human half-life of up to 100 days, suggesting the possibility of dosing only twice a year.

Therapeutic Potential: The unique mechanism of action of IBIO-610 may provide a more comprehensive treatment for obesity and cardiometabolic diseases, addressing gaps left by current GLP-1 therapies.

Presentation at ObesityWeek: The findings will be presented at ObesityWeek 2025, highlighting the potential of IBIO-610 to improve patient experience with less frequent dosing and reduced side effects compared to existing treatments.

iBio's Conference Participation: iBio, Inc. will participate in the Guggenheim 2nd Annual Healthcare Innovation Conference from November 10–12, 2025, where CEO Martin Brenner will discuss the company's advancements in becoming a clinical-stage biotechnology firm and its obesity pipeline.

Focus on Obesity Treatments: During the conference, Dr. Brenner will highlight iBio's differentiated antibody programs aimed at complementing existing obesity therapies and creating long-term value through innovation.

One-on-One Meetings: CFO Felipe Duran will join Dr. Brenner for one-on-one meetings with attendees at the conference, providing further insights into the company's strategies and developments.

Company Overview: iBio is a biotech company utilizing AI and advanced computational biology to develop innovative biopharmaceuticals for various diseases, including obesity and cancer, with a mission to transform drug discovery and accelerate development timelines.

Ventyx Biosciences Surge: Ventyx Biosciences' shares skyrocketed over 88% after positive Phase 2 trial results for its obesity and cardiovascular risk treatment, VTX3232.

Medpace Holdings Performance: Medpace Holdings saw an 18% increase in shares following better-than-expected Q3 results and an updated fiscal year 2025 guidance.

Inhibrx Biosciences Update: Inhibrx Biosciences' shares rose over 10% as the company announced a live webcast to present topline results from its ChonDRAgon study on ozekibart for chondrosarcoma.

Other Notable Movers: Several biotech stocks, including Acumen Pharmaceuticals and SCYNEXIS, experienced significant after-hours gains, reflecting a broader positive trend in the sector.

iBio Presentations: iBio, Inc. will present research on its Activin E antibody, IBIO-610, at ObesityWeek 2025 and PEGS Europe 2025, highlighting its potential for treating obesity and enhancing current therapies.

Research Findings: The data from non-human primate studies suggest that IBIO-610 may enable fat-selective weight loss, support long-term weight maintenance, and improve the efficacy of GLP-1 therapies.

Presentation Details: Cory Schwartz will present on November 4, 2025, at ObesityWeek, while Martin Brenner will present on November 12, 2025, at PEGS Europe, discussing the innovative approaches to obesity treatment.

Company Overview: iBio is a biotech firm focused on developing advanced biopharmaceuticals for cardiometabolic diseases, utilizing AI and computational biology to create breakthrough antibody treatments.

Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make winning trades in the stock market.

Exclusive Community: Joining Benzinga Pro connects users with over 10,000 serious traders and provides access to exclusive stories and accurate market intelligence.